199 related articles for article (PubMed ID: 15169982)
1. Indications for imatinib mesylate therapy and clinical management.
Guilhot F
Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
4. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
7. Imatinib Mesylate.
Waller CF
Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
[TBL] [Abstract][Full Text] [Related]
8. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
[TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome after treatment with STI571: a case report.
Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
[TBL] [Abstract][Full Text] [Related]
10. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Druker BJ
Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776
[TBL] [Abstract][Full Text] [Related]
11. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
12. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
13. [Hematological side effects of tyrosine kinase inhibition using imatinib].
Schmitt-Graeff A; Hochhaus A
Pathologe; 2006 Feb; 27(1):40-6. PubMed ID: 16421705
[TBL] [Abstract][Full Text] [Related]
14. Pityriasis rosea associated with imatinib (STI571, Gleevec).
Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
[TBL] [Abstract][Full Text] [Related]
15. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
16. Gleevec: tailoring to fit.
May TS
Drug Discov Today; 2003 Mar; 8(5):188-9. PubMed ID: 12634004
[No Abstract] [Full Text] [Related]
17. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Baskaynak G; Kreuzer KA; Schwarz M; Zuber J; Audring H; Riess H; Dörken B; le Coutre P
Eur J Haematol; 2003 Apr; 70(4):231-4. PubMed ID: 12656746
[TBL] [Abstract][Full Text] [Related]
18. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
[TBL] [Abstract][Full Text] [Related]
19. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
20. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
